Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R; Israel Shigella Study Group. Passwell JH, et al. Pediatr Infect Dis J. 2003 Aug;22(8):701-6. doi: 10.1097/01.inf.0000078156.03697.a5. Pediatr Infect Dis J. 2003. PMID: 12913770 Clinical Trial.
O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.
Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH. Chowers Y, et al. Among authors: passwell jh. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2396-401. doi: 10.1073/pnas.0610833104. Epub 2007 Feb 7. Proc Natl Acad Sci U S A. 2007. PMID: 17287349 Free PMC article. Clinical Trial.
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group. Passwell JH, et al. Vaccine. 2010 Mar 2;28(10):2231-2235. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5. Vaccine. 2010. PMID: 20056180 Free PMC article. Clinical Trial.
Shigella lipopolysaccharide antibodies in pediatric populations.
Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S. Passwell JH, et al. Pediatr Infect Dis J. 1995 Oct;14(10):859-65. doi: 10.1097/00006454-199510000-00008. Pediatr Infect Dis J. 1995. PMID: 8584312
Erratum to 'Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children' [Vaccine 28 (2010) 2231-2235].
Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group. Passwell JH, et al. Vaccine. 2019 Aug 23;37(36):5504. doi: 10.1016/j.vaccine.2019.07.065. Epub 2019 Aug 1. Vaccine. 2019. PMID: 31378536 Free PMC article. No abstract available.
107 results